DHR

DANAHER CORP

Apr 05 • 04:00PM ET

196.11

+5.16 (+2.70%)

Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. It operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment offers bioprocessing technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration techno ... read more

Full Time Employees 61,000

Phone 202 828 0850

Website https://www.danaher.com

CEO Mr. Rainer M. Blair

IPO Date 1978-12-29

Sector Healthcare

Industry Medical - Diagnostics & Research

Address 2200 Pennsylvania Avenue, NW, Washington, DC 20037-1701

Balance Sheet

Total Cash $1,993,000,000

Total Debt $16,477,000,000

Current Ratio 1.43

Quick Ratio 0.83

Profitability

Gross Margin 59.74%

Net Margin 15.81%

ROE 7.40%

ROA 4.76%

ROIC 5.99%

Balance Sheet

Total Cash $1,993,000,000

Total Debt $16,477,000,000

Current Ratio 1.43

Quick Ratio 0.83

Profitability

Gross Margin 59.74%

Net Margin 15.81%

ROE 7.40%

ROA 4.76%

ROIC 5.99%

Name	DANAHER CORP	Sector	Healthcare	Currency	USD	Relative Volume	1.6	Market Cap	129912
Current Ratio	1.4	Dividend / Share	1.08	EPS	5.29	Revenue	23875000000	P/S	5.4
P/E	33.3	Beta	0.59	Income	3899000000	Volume	7077499	Average Volume	4410278
Distance to 200DMA	-25.16%	200 DMA	242.89	50 DMA	210.8	ROA	4.9	ROE	7.6
Distance to 50DMA	-13.77%	Return 1Y	-25.25%	Return YTD	-20.69%	Forward PE		Qtly Growth YOY
Debt/Eq	0.56	P/B	2.6	Dividend Yield	0.5%	Net Margin	16.33%	Payout Ratio	20.3

Performance

52 Week Range 20.3%

Distance to 200DMA 0.14%

Day Change Percent $0.27

Performance Week $0.27

Performance Month $0.27

Performance Quarter 2024-06-28

Performance YTD $0.27

Performance Year $0.27

Performance Range

Day

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Month

$196

Current

Low: High:

Balance Sheet

Total Cash $2,627,000,000

Total Debt $17,524,000,000

Current Ratio 1.37%

Quick Ratio 0.84%

Profitability

Valuation

Price to Earnings 37.31

Price to Book 2.76

Price to Sales 5.90

Price to Free Cash Flow 28.55

Dividends

Payout Ratio 21.50%

Dividend Yield 0.58%

Dividend Amount $0.27

Last Dividend Pay Date 2024-06-28

Last Dividend Paid $0.27

Performance

52 Week Range 20.3%

Distance to 200DMA 0.14%

Day Change Percent $0.27

Performance Week $0.27

Performance Month $0.27

Performance Quarter 2024-06-28

Performance YTD $0.27

Performance Year $0.27

Company Profile

Full Time Employees 61,000

Phone 202 828 0850

Website https://www.danaher.com

CEO Mr. Rainer M. Blair

IPO Date 1978-12-29

Sector Healthcare

Address 2200 Pennsylvania Avenue, NW, Washington, DC 20037-1701

Histogram - Daily

Balance Sheet

Total Cash $2,627,000,000

Total Debt $17,524,000,000

Current Ratio 1.37%

Quick Ratio 0.84%

Profitability

Gross Margin 0.5960%

Net Margin 0.1940%

ROE 0.07%

ROA 0.05%

Company Profile

Full Time Employees 61,000

Phone 202 828 0850

Website https://www.danaher.com

CEO Mr. Rainer M. Blair

IPO Date 1978-12-29

Sector Healthcare

Address 2200 Pennsylvania Avenue, NW, Washington, DC 20037-1701

Monthly Win Rate

Balance Sheet (Multi-Column Example)

	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023	Mar 2023
Cash & Short Term Investments	53,775.0	65,171.0	61,801.0	67,150.0	73,100.0	61,555.0	62,482.0	55,872.0
Receivables	59,306.0	66,243.0	43,172.0	41,150.0	50,102.0	60,985.0	39,186.0	35,899.0
Inventory	6,911.0	7,286.0	6,165.0	6,232.0	6,511.0	6,331.0	7,351.0	7,482.0

Latest News

Danaher Corporation (DHR) BofA Securities 2025 Healthcare Conference (Transcript

Danaher Corporation (NYSE:DHR ) BofA Securities 2025 Healthcare Conference May 15, 2025 1:00 PM ET Company Participants Rainer Blair - CEO Conference Call Participants Mike Ryskin - Bank of America Mi

2025-05-15 15:32:06 - seekingalpha.com

CVS vs. DHR: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Services sector might want to consider either CVS Health (CVS) or Danaher (DHR). But which of these two companies is the best option for those looking for u

2025-05-09 12:40:37 - zacks.com

Danaher to Present at Bank of America Securities Healthcare Conference

WASHINGTON , May 7, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced that President and Chief Executive Officer, Rainer M. Blair, will be presenting at the at the Bank of America Securit

2025-05-07 16:15:00 - prnewswire.com

Danaher Announces Quarterly Dividend

WASHINGTON , May 6, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) announced today that its Board of Directors has approved a regular quarterly cash dividend of $0.32 per share of its common sto

2025-05-06 16:15:00 - prnewswire.com

Danaher: A Capital Intensive Business Offering Low Risk, Low Reward Opportunity

Danaher Corporation's intrinsic value is estimated at $213 per share, suggesting a 14% upside from the current price of $187, with a 12% margin of safety. Despite revenue growth driven by acquisitions

2025-05-06 08:34:13 - seekingalpha.com

Danaher: Q1 Beat Fails To Trigger Guidance Upgrade

Danaher's management appears to be strategically keeping the stock price depressed to complete its share buyback program and capitalize on lower acquisition target valuations. The company delivered be

2025-05-02 04:00:50 - seekingalpha.com

Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collabora

Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies. High transgene expression and improved safety profile of Aldveron's Nanoplasmi

2025-04-29 10:07:00 - prnewswire.com

BLCO or DHR: Which Is the Better Value Stock Right Now?

Investors interested in stocks from the Medical Services sector have probably already heard of Bausch + Lomb (BLCO) and Danaher (DHR). But which of these two stocks presents investors with the better

2025-04-23 12:40:38 - zacks.com

Danaher Q1 Earnings Beat Estimates, Life Sciences Sales Down Y/Y

DHR's first-quarter sales decrease 1% year over year, due to the lackluster performance of its Life Sciences and Biotechnology segments.

2025-04-22 13:15:37 - zacks.com

Danaher Corporation (DHR) Q1 2025 Earnings Call Transcript

Danaher Corporation (NYSE:DHR ) Q1 2025 Earnings Conference Call April 22, 2025 8:00 AM ET Company Participants John Bedford - VP, IR Rainer Blair - President & CEO Matt McGrew - EVP & CFO Conference

2025-04-22 11:09:47 - seekingalpha.com

Danaher (DHR) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Danaher (DHR) give insight into how the company performed in the quarter ended March 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates

2025-04-22 10:36:39 - zacks.com

Danaher Beats Q1 Expectations, Signals Caution Ahead In 'Unusual Times'

Danaher Corp DHR on Tuesday reported first-quarter 2025 sales of $5.74 billion, down 1% year-over-year, beating the consensus of $5.59 billion.

2025-04-22 08:57:17 - benzinga.com

Danaher Reports First Quarter 2025 Results

WASHINGTON , April 22, 2025 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the quarter ended March 28, 2025. Key First Quarter 2025 Results Net earnings we

2025-04-22 06:00:00 - prnewswire.com

Danaher Gears Up to Post Q1 Earnings: Is a Beat in Store?

DHR's first-quarter earnings are likely to have been aided by strength in the Biotechnology segment. However, weakness in the Diagnostics and Life Sciences segments are expected to have hurt.

2025-04-21 11:20:47 - zacks.com